Development of macrophage targeting inhaled tigecycline dry powder formulation for treating non-tuberculous mycobacterial (NTM) infections
Active Grant Awarded
- Award ID
- R43AI197715
- Recipient
-
Via Therapeutics, LLC UEI YHRZATLXKL46
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $313,674
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 21% complete
- Place of performance
- Austin, TX 78750, USA
Award details come from USAspending.gov.
About this award
The National Institutes of Health's National Institute of Allergy and Infectious Diseases, part of the U.S. Department of Health and Human Services, awarded Grant R43AI197715 to Via Therapeutics, LLC on September 9, 2026, with $313,674 obligated under Assistance Listing 93.855, Allergy and Infectious Diseases Research. The award funds development of a macrophage-targeting, inhaled tigecycline dry powder formulation for treating non-tuberculous mycobacterial (NTM) infections. The project summary cites a 7.5% annual rise in NTM pulmonary disease incidence and treatment regimens that rely on three antibiotics over 12 to 18 months, with recurrence rates of 10% to 60%. Tigecycline is active against NTM, including M. abscessus, but its use is hindered by the need for intravenous administration and high-dose toxicity, which the inhaled formulation targets. Work is performed in Austin, Texas (78750), and the period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2027. The assistance type is a grant.
Description
- Abstract
- The incidence of non-tuberculous mycobacteria (NTM) pulmonary disease is rising globally at an increased incidence rate of 7.5% per year, and its treatment is challenging due to the limited efficacy and high toxicity of available drugs. NTM, similar to other deadly pathogens, has the ability to form biofilms that increases the amount of antibiotics needed to treat the infections with some studies finding a six-fold increase. Additionally, the highly lipid dense cell wall limits the penetration of some antibiotic classes. Also, NTM has shown the ability to affect phagosome maturation leading to possible replication, escape, and survival of the microorganism. An additional complication of the intracellular NTM infection is that macrophages can impede the penetration of some antibiotic classes reducing the efficacy of the delivered antibiotics. M. Abscessus has been labeled an "antibiotic nightmare" because of the ineffectiveness of available antibiotics and the current practice of using multiple combinations of agents with high side effect profiles. Available in vitro data suggest limited to no activity of most antibiotics and in patient's treatment success rates of less than 50%. Despite the limited treatment success, the current protocols rely on a three antibiotic regimen that needs to be delivered over a 12-18-month period with high recurrence rates between 10-60%. The ineffective treatments come with considerable costs ranging from USD $14,730 to USD $47,240. Alternative therapies have been investigated to address the shortcomings of the current treatments; tigecycline (TIG) is active against NTM, including M. Abscessus, which is particularly hard to treat due to high resistance. However, TIG's use is hindered by the need for IV administration, requiring high doses that result in significant toxicity (>90% report adverse effects), its poor stability in aqueous environments and limited targeting to intracellular NTM. Additionally, tigecycline is prone to degradation, limiting its clinical usefulness, and reducing its commercialization due to degradation during certain processing procedures. Inhalation of TIG could overcome these barriers by achieving high local drug concentrations while targeting intracellular NTM infections through formulation approaches. We propose developing a dry powder inhalation (DPI) therapy for TIG, targeting alveolar macrophages by delaying dissolution, and ensuring effective delivery regardless of inhalation force. Additionally, the use of jet milling for the processing of the powder formulation greatly reduces the degradation that can occur during spray drying. Our aims include optimizing the formulation and processing, evaluating suitable inhalers, and conducting pharmacokinetic and efficacy studies in state-of- the-art animal models. This system could reduce adverse effects and treatment duration, serving as a potential adjunct therapy for NTM.
Quick answers
Who received award R43AI197715?
R43AI197715 was awarded to Via Therapeutics, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 9, 2026.
How much is award R43AI197715 worth?
$313,674 has been obligated on R43AI197715.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award